Prolonged opportunity for ischemic neuroprotection with selective κ-opioid receptor agonist in rats

Tsung Ying Chen, Toru Goyagi, Thomas J K Toung, Jeffrey R. Kirsch, Patricia D. Hurn, Raymond C. Koehler, Anish Bhardwaj

Research output: Contribution to journalArticle

43 Citations (Scopus)

Abstract

Background and Purpose - We have previously demonstrated that pretreatment with selective κ-opioid agonist BRL 52537 hydrochloride [(±)-1-(3,4-dichlorophenyl) acetyl-2-(1-pyrrolidinyl) methylpiperidine], provides ischemic neuroprotection following transient focal ischemia in rats. The present study was undertaken to a) define "therapeutic opportunity" for ischemic neuroprotection with BRL 52537, and b) determine if BRL 52537 attenuates ischemia-evoked efflux of dopamine and its metabolites in the striatum in vivo following transient focal ischemia. Methods - Using the intraluminal filament technique, halothane-anesthetized male Wistar rats were subjected to 2 hours of middle cerebral artery occlusion (MCAO). In a blinded, randomized fashion, rats were treated with saline (vehicle) or 1 mg/Kg/hr BRL 52537 infusion for 22 hours, initiated at onset, 2, 4, or 6 hours of reperfusion (Rep). In a separate set of experiments utilizing in vivo microdialysis, extracellular levels of dopamine and its metabolites were determined in the striatum during 2 hours of MCAO and 3 hours of reperfusion. Results - Infarct volume (% of contralateral structure; mean ±SEM) in cortex was significantly attenuated when BRL 52537 was administered at reperfusion (22±6%), 2 hours (21±6%), and 4 hours (18±5%) compared with controls (39±5%). In striatum, infarct volume was significantly attenuated when BRL 52537 was administered at reperfusion (38±9%), 2 hours (40±8%), 4 hours (50±8%), and 6 hours (46±9%) as compared with controls (70±4%). A 6- to 8-fold increase in dopamine in microdialysates occurred within 40 minutes of MCAO. Pretreatment with BRL 52537 did not alter microdialysate levels of dopamine or its metabolites in the striatum during MCAO and early reperfusion, as compared with saline controls. Conclusions - These data demonstrate that BRL 52537 provides robust ischemic neurprotection with a long therapeutic opportunity (at least 6 hours) without altering ischemia-evoked efflux of dopamine (DA) and its metabolites in striatum during ischemia and early reperfusion.

Original languageEnglish (US)
Pages (from-to)1180-1185
Number of pages6
JournalStroke
Volume35
Issue number5
DOIs
StatePublished - May 2004
Externally publishedYes

Fingerprint

Opioid Receptors
Reperfusion
Middle Cerebral Artery Infarction
Dopamine
Ischemia
1-(3,4-dichlorophenyl)acetyl-2-(1-pyrrolidinyl)methylpiperidine
Neuroprotection
Microdialysis
Halothane
Opioid Analgesics
Wistar Rats
Therapeutics

Keywords

  • Infarct
  • Ischemia
  • Kappa(1) opioid receptors
  • Neuroprotection
  • Reperfusion

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Neuroscience(all)

Cite this

Chen, T. Y., Goyagi, T., Toung, T. J. K., Kirsch, J. R., Hurn, P. D., Koehler, R. C., & Bhardwaj, A. (2004). Prolonged opportunity for ischemic neuroprotection with selective κ-opioid receptor agonist in rats. Stroke, 35(5), 1180-1185. https://doi.org/10.1161/01.STR.0000125011.93188.c6

Prolonged opportunity for ischemic neuroprotection with selective κ-opioid receptor agonist in rats. / Chen, Tsung Ying; Goyagi, Toru; Toung, Thomas J K; Kirsch, Jeffrey R.; Hurn, Patricia D.; Koehler, Raymond C.; Bhardwaj, Anish.

In: Stroke, Vol. 35, No. 5, 05.2004, p. 1180-1185.

Research output: Contribution to journalArticle

Chen, Tsung Ying ; Goyagi, Toru ; Toung, Thomas J K ; Kirsch, Jeffrey R. ; Hurn, Patricia D. ; Koehler, Raymond C. ; Bhardwaj, Anish. / Prolonged opportunity for ischemic neuroprotection with selective κ-opioid receptor agonist in rats. In: Stroke. 2004 ; Vol. 35, No. 5. pp. 1180-1185.
@article{a885a8c7599545c29b96a385695b1deb,
title = "Prolonged opportunity for ischemic neuroprotection with selective κ-opioid receptor agonist in rats",
abstract = "Background and Purpose - We have previously demonstrated that pretreatment with selective κ-opioid agonist BRL 52537 hydrochloride [(±)-1-(3,4-dichlorophenyl) acetyl-2-(1-pyrrolidinyl) methylpiperidine], provides ischemic neuroprotection following transient focal ischemia in rats. The present study was undertaken to a) define {"}therapeutic opportunity{"} for ischemic neuroprotection with BRL 52537, and b) determine if BRL 52537 attenuates ischemia-evoked efflux of dopamine and its metabolites in the striatum in vivo following transient focal ischemia. Methods - Using the intraluminal filament technique, halothane-anesthetized male Wistar rats were subjected to 2 hours of middle cerebral artery occlusion (MCAO). In a blinded, randomized fashion, rats were treated with saline (vehicle) or 1 mg/Kg/hr BRL 52537 infusion for 22 hours, initiated at onset, 2, 4, or 6 hours of reperfusion (Rep). In a separate set of experiments utilizing in vivo microdialysis, extracellular levels of dopamine and its metabolites were determined in the striatum during 2 hours of MCAO and 3 hours of reperfusion. Results - Infarct volume ({\%} of contralateral structure; mean ±SEM) in cortex was significantly attenuated when BRL 52537 was administered at reperfusion (22±6{\%}), 2 hours (21±6{\%}), and 4 hours (18±5{\%}) compared with controls (39±5{\%}). In striatum, infarct volume was significantly attenuated when BRL 52537 was administered at reperfusion (38±9{\%}), 2 hours (40±8{\%}), 4 hours (50±8{\%}), and 6 hours (46±9{\%}) as compared with controls (70±4{\%}). A 6- to 8-fold increase in dopamine in microdialysates occurred within 40 minutes of MCAO. Pretreatment with BRL 52537 did not alter microdialysate levels of dopamine or its metabolites in the striatum during MCAO and early reperfusion, as compared with saline controls. Conclusions - These data demonstrate that BRL 52537 provides robust ischemic neurprotection with a long therapeutic opportunity (at least 6 hours) without altering ischemia-evoked efflux of dopamine (DA) and its metabolites in striatum during ischemia and early reperfusion.",
keywords = "Infarct, Ischemia, Kappa(1) opioid receptors, Neuroprotection, Reperfusion",
author = "Chen, {Tsung Ying} and Toru Goyagi and Toung, {Thomas J K} and Kirsch, {Jeffrey R.} and Hurn, {Patricia D.} and Koehler, {Raymond C.} and Anish Bhardwaj",
year = "2004",
month = "5",
doi = "10.1161/01.STR.0000125011.93188.c6",
language = "English (US)",
volume = "35",
pages = "1180--1185",
journal = "Stroke",
issn = "0039-2499",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Prolonged opportunity for ischemic neuroprotection with selective κ-opioid receptor agonist in rats

AU - Chen, Tsung Ying

AU - Goyagi, Toru

AU - Toung, Thomas J K

AU - Kirsch, Jeffrey R.

AU - Hurn, Patricia D.

AU - Koehler, Raymond C.

AU - Bhardwaj, Anish

PY - 2004/5

Y1 - 2004/5

N2 - Background and Purpose - We have previously demonstrated that pretreatment with selective κ-opioid agonist BRL 52537 hydrochloride [(±)-1-(3,4-dichlorophenyl) acetyl-2-(1-pyrrolidinyl) methylpiperidine], provides ischemic neuroprotection following transient focal ischemia in rats. The present study was undertaken to a) define "therapeutic opportunity" for ischemic neuroprotection with BRL 52537, and b) determine if BRL 52537 attenuates ischemia-evoked efflux of dopamine and its metabolites in the striatum in vivo following transient focal ischemia. Methods - Using the intraluminal filament technique, halothane-anesthetized male Wistar rats were subjected to 2 hours of middle cerebral artery occlusion (MCAO). In a blinded, randomized fashion, rats were treated with saline (vehicle) or 1 mg/Kg/hr BRL 52537 infusion for 22 hours, initiated at onset, 2, 4, or 6 hours of reperfusion (Rep). In a separate set of experiments utilizing in vivo microdialysis, extracellular levels of dopamine and its metabolites were determined in the striatum during 2 hours of MCAO and 3 hours of reperfusion. Results - Infarct volume (% of contralateral structure; mean ±SEM) in cortex was significantly attenuated when BRL 52537 was administered at reperfusion (22±6%), 2 hours (21±6%), and 4 hours (18±5%) compared with controls (39±5%). In striatum, infarct volume was significantly attenuated when BRL 52537 was administered at reperfusion (38±9%), 2 hours (40±8%), 4 hours (50±8%), and 6 hours (46±9%) as compared with controls (70±4%). A 6- to 8-fold increase in dopamine in microdialysates occurred within 40 minutes of MCAO. Pretreatment with BRL 52537 did not alter microdialysate levels of dopamine or its metabolites in the striatum during MCAO and early reperfusion, as compared with saline controls. Conclusions - These data demonstrate that BRL 52537 provides robust ischemic neurprotection with a long therapeutic opportunity (at least 6 hours) without altering ischemia-evoked efflux of dopamine (DA) and its metabolites in striatum during ischemia and early reperfusion.

AB - Background and Purpose - We have previously demonstrated that pretreatment with selective κ-opioid agonist BRL 52537 hydrochloride [(±)-1-(3,4-dichlorophenyl) acetyl-2-(1-pyrrolidinyl) methylpiperidine], provides ischemic neuroprotection following transient focal ischemia in rats. The present study was undertaken to a) define "therapeutic opportunity" for ischemic neuroprotection with BRL 52537, and b) determine if BRL 52537 attenuates ischemia-evoked efflux of dopamine and its metabolites in the striatum in vivo following transient focal ischemia. Methods - Using the intraluminal filament technique, halothane-anesthetized male Wistar rats were subjected to 2 hours of middle cerebral artery occlusion (MCAO). In a blinded, randomized fashion, rats were treated with saline (vehicle) or 1 mg/Kg/hr BRL 52537 infusion for 22 hours, initiated at onset, 2, 4, or 6 hours of reperfusion (Rep). In a separate set of experiments utilizing in vivo microdialysis, extracellular levels of dopamine and its metabolites were determined in the striatum during 2 hours of MCAO and 3 hours of reperfusion. Results - Infarct volume (% of contralateral structure; mean ±SEM) in cortex was significantly attenuated when BRL 52537 was administered at reperfusion (22±6%), 2 hours (21±6%), and 4 hours (18±5%) compared with controls (39±5%). In striatum, infarct volume was significantly attenuated when BRL 52537 was administered at reperfusion (38±9%), 2 hours (40±8%), 4 hours (50±8%), and 6 hours (46±9%) as compared with controls (70±4%). A 6- to 8-fold increase in dopamine in microdialysates occurred within 40 minutes of MCAO. Pretreatment with BRL 52537 did not alter microdialysate levels of dopamine or its metabolites in the striatum during MCAO and early reperfusion, as compared with saline controls. Conclusions - These data demonstrate that BRL 52537 provides robust ischemic neurprotection with a long therapeutic opportunity (at least 6 hours) without altering ischemia-evoked efflux of dopamine (DA) and its metabolites in striatum during ischemia and early reperfusion.

KW - Infarct

KW - Ischemia

KW - Kappa(1) opioid receptors

KW - Neuroprotection

KW - Reperfusion

UR - http://www.scopus.com/inward/record.url?scp=2142698060&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=2142698060&partnerID=8YFLogxK

U2 - 10.1161/01.STR.0000125011.93188.c6

DO - 10.1161/01.STR.0000125011.93188.c6

M3 - Article

C2 - 15031456

AN - SCOPUS:2142698060

VL - 35

SP - 1180

EP - 1185

JO - Stroke

JF - Stroke

SN - 0039-2499

IS - 5

ER -